WebOct 12, 2016 · CPI-613 is a novel anti-cancer agent that selectively inhibits the altered form of mitochondrial energy metabolism in tumor cells. Methods We evaluated CPI-613 with … WebNov 16, 2024 · The FDA granted fast track designation to devimistat for the treatment of pancreatic cancer, according to the agent’s manufacturer.Devimistat (CPI-613, Rafael …
Innovative Cancer Therapies Cornerstone Pharmaceuticals
WebDec 2, 2016 · In a historical cohort, only 19% (3/16) of patients with poor risk cytogenetics responded with a median survival of 2.8 months (Figure 1). The most common toxicities of CPI-613 were diarrhea and nausea. Thirteen patients (21%) went on to allogeneic stem cell transplantation. Several patients had blood samples taken before and after CPI-613 ... WebArm: Experimental Radiation Intensity-modulated Radiation Therapy Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 … suffield elementary school
Abstract PO-024: Targeting cellular metabolism with CPI-613 …
WebApr 28, 2024 · CPI-613-treated or non-treated cells were incubated with JC-1 (1:1000 dilution) for 20 min at 37 °C. After PBS washing, cells were observed under a fluorescence microscope with the red fluorescence (550 nm excitation/600 nm emission) and green fluorescence channels (485 nm excitation/535 nm emission). WebMay 26, 2024 · Rafael Pharmaceuticals’ lead compound, CPI-613® (devimistat), is a highly selective, well-tolerated and effective anti-cancer agent that is being evaluated in ongoing and completed Phase 1, 2 ... WebNov 1, 2024 · with either CPI-613 alone, radiation alone, or a combina-tion of both for 72 hours. After treatment, cells were tryp-sinized and 500 cells were replated in 6-well plates for an. additional 10 days. paint-on graphite undercoating